Commitments and Contingencies (Details Narrative) - USD ($) |
1 Months Ended | 9 Months Ended |
|---|---|---|
Aug. 28, 2019 |
Sep. 30, 2021 |
|
| Research and development agreement | $ 550,000 | |
| Damages amount | $ 1,670,000 | |
| Represent shares of common stock | 882,353 | 882,353 |
| Accrued expenses | $ 100,000 | |
| Royalty payments beginning in 2022 | 250,000 | |
| Royalty payments beginning in 2025 | 2,000,000.0 | |
| Royalty payments beginning in 2027 | 5,000,000.0 | |
| Certain milestone payments totaling | $ 3,100,000 | |
| Minimum [Member] | ||
| Upfront license fees | 5.00% | |
| Maximum [Member] | ||
| Upfront license fees | 6.00% |
| X | ||||||||||
- Definition Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer. No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The value (monetary amount) of the award the plaintiff seeks in the legal matter. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of other research and development expense. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|